Rheumatoid Arthritis patents
This page is updated frequently with new Rheumatoid Arthritis-related patent applications.
|Methods of treating kawasaki disease using il-1b antibodies|
This invention relates to a novel use of il-1β-ligand/il-1 receptor disrupting compounds (herein referred to as “il-1 beta compounds”); such as small molecular compounds disrupting il-1b ligand-il-1 receptor interaction, il-1b antibodies or il-1 receptor antibodies, e.g. Il-1b binding molecules described herein, e.g.
|Anti-activin a antibodies and uses thereof|
The disclosure provides compositions and methods relating to or derived from anti-activin a binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin a antibodies that bind human activin a, activin a-binding fragments and derivatives of such antibodies, and activin a-binding polypeptides comprising such fragments.
|New pyrazolyl-substituted heteroaryls and their use as medicaments|
And the use of these aforementioned compounds for the treatment of diseases such as asthma, copd, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.. .
|Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent|
The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—free-b-ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions mediated by the cox-2 and 5-lo pathways. The present invention further provides a novel method for simultaneously inhibiting the cyclooxygenase-2 (cox-2) and 5-lipoxygenase (5-lo) enzymes, and reducing cox-2 mrna production.
|Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis|
The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular
|Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases|
A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, huntington's disease, epilepsy, multiple sclerosis (ms), lupus, type-1 and type-2 diabetes, maturity onset diabetes of the young (mody), myasthenia gravis (mg), rheumatoid arthritis (ra), graves' disease, guillain-barré syndrome (gbs), metabolic syndrome, muscular dystrophy or duchenne muscular dystrophy (dmd), severe burns, aging, amyotrophic lateral sclerosis (als), friedreich's ataxia, batten disease, alzheimer's disease, optic neuritis, leber's hereditary optic neuropathy (lhon), autism, rett syndrome, batten disease, angelman's syndrome, leigh disease, fragile-x syndrome, depression, parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous bdnf expression with dnp treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. Dnp was administered to mice daily over a range of doses, and subsequently bdnf expression in the brain showed a dose dependent and non-linear increase in expression..
Mitochon Pharmaceuticals, Inc.
|Substituted pyridazines as prostacyclin receptor modulators|
Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.
|Method for the serological diagnosis of rheumatoid arthritis|
This disclosure relates to the field of diagnostic methods. A new marker antibody for rheumatoid arthritis, as well as a new method for detecting rheumatoid arthritis, is disclosed herein.
|Integrin-blocking polypeptides and uses thereof|
A series of integrin blockers that present strong angiogenesis inhibiting performance, high integrin affinity and integrin-bonding capacity is provided. This series of integrin blockers can be adopted in treatment of solid tumors and rheumatoid arthritis.
The invention relates to a compound of formula (i) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (i) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, type i diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, crohn's disease, alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals..
Novartis Tiergesundheit Ag
3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
(wherein r1, r2, r3, r4, r5, r6, r7, x, y and z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the ccr2 and/or ccr5 receptor.
Compositions containing extracts of curcuma longa and echinacea angustifolia which are useful to reduce peripheral inflammation and pain
The present invention relates to compositions containing, as their only active ingredients, an extract of curcuma spp, optionally as curcumin in the form of a complex with phospholipids, and an extract selected from echinacea spp extract or lipophilic extract of zanthoxylum spp, which are useful in the topical and systemic treatment of peripheral pain and of superficial and deep inflammatory and painful conditions. The compositions according to the invention are particularly effective in the treatment of osteoarthritis and rheumatoid arthritis in patients unable to tolerate long-term treatment with nsaids or steroids..
Methods for the diagnostic of an autoimmune disease
An in vitro method for determining whether a patient has, or is at risk of having or developing an autoimmune disease or for assessing the severity or predicting the outcome of an autoimmune disease, comprising a step of detecting or quantifying in a biological sample obtained from said patient an immune anti-il2 response, peptides specifically recognised by anti-il2 antibodies or il-2-specific t cells of t1d, systemic lupus erythematosus, rheumatoid arthritis, sjögren's syndrome and autoimmune polymyositis patients, and pharmaceutical compositions.. .
Universite Paris Descartes
Selective glucocorticoid receptor ligands
Described herein are certain steroid derivative compounds, for example of formula (i): wherein x1, x2, x3 l, and ar are as defined herein, pharmaceutical compositions comprising such compounds, the use of such compounds and compositions to specifically target glucocorticoid action, and the use of such compounds and compositions in the treatment of acute and chronic inflammatory conditions, in particular rheumatoid arthritis, haematological and other malignancies, and for causing immunosuppression in the prevention or treatment of transplant rejection, as well as methods of preparing such compounds.. .
The University Of Manchester
Use of ctla4 compound for achieving drug-free remission in subjects with early ra
The present invention is directed to methods and compositions for achieving drug-free remission in subjects with early ra by administering to a subject in need thereof an effective amount of soluble ctla4 molecule until disease activity score calculator for rheumatoid arthritis (das)-defined remission is achieved and then withdrawing the ra therapy.. .
Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
The disclosure relates to prostaglandin receptor ep2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which ep2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof..
Antibody therapeutics that bind cd147
There is disclosed compositions and methods relating to or derived from anti-cd147 antibodies. More specifically, there is disclosed fully human antibodies that bind cd147, cd147-binding fragments and derivatives of such antibodies, and cd147-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.
Anti-human il-21 antibodies
Monoclonal antibodies are identified that bind the il-21 protein. These antibodies are used to identify regions of the il-21 protein to where binding neutralizes il-21 activity.
Novel compounds useful for the treatment of degenerative and inflammatory diseases
The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. Asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g.
Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
The present invention is based on the discovery of genetic polymorphisms that are associated with rheumatoid arthritis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection..
Mmf-derivatives of ethyleneglycols
The present invention relates to novel compounds, e.g. For use as a medicament.
Surrogates of post-translationally modified proteins and uses thereof
The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins.
President And Fellows Of Harvard College
Methods of treating inflammatory and autoimmune diseases with natalizumab
Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, crohn's disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment.
Prodrug of an ice inhibitor
Compound i is useful for treating il-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, alzheimer's disease, myocardial infarction, congestive heart failure, huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.. .
Aryl and heteroaryl ether compounds as ror gamma modulators
The present disclosure is directed to compounds of formula (i) and pharmaceutically acceptable salts thereof, wherein ring a, ring b, r, r2, r3, n, and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (rorγt). These compounds prevent, inhibit, or suppress the action of rorγt and are therefore useful in the treatment of rorγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, copd, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer..
Glenmark Pharmaceuticals S.a.
Ddx5 and associated non-coding rnas and modulation of th17 effector function
Methods for screening to identify agents capable of modulating ddx5 polypeptide activity are encompassed herein as are methods for using such agents to treat subjects afflicted with th17-mediated inflammatory conditions and autoimmune diseases including, without limitation, crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis, and psoriasis and methods for using such agents to treat subjects afflicted with cancer.. .
Marker sequences for rheumatoid arthritis and use thereof
The present invention relates to new marker sequences for rheumatoid arthritis and the diagnostic use thereof together with a method for screening of potential active substances for rheumatoid arthritis by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for rheumatoid arthritis, in particular a protein biochip and the use thereof..
Heteroaryl syk inhibitors
The invention relates to new substituted heteroaryls of formula 1 wherein a is selected from the group consisting of n and ch d is selected from the group consisting of ch, n, nh, e is c, t is selected from the group consisting of c and n, g is selected from the group consisting of c and n, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein r1, m and r3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, copd, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.. .
Boehringer Ingelheim International Gmbh
Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
The present invention provides a heterocyclic compound having a tlr7, tlr9, tlr7/8, tlr7/9 or tlr7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof..
Takeda Pharmaceutical Company Limited
Treatment of inflammatory diseases using placental stem cells
Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (alibert-bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.. .
Diagnostic and immunotherapy compositions and methods for disease states mediated by inhibitor-resistant cd8 t-cells
A previously unknown t cell receptor (tcr) activation pathway dependent on the aryl hydrocarbon receptor conferring resistance to calcineurin inhibitors and mtor inhibitors is disclosed, including application of this pathway to the diagnosis and treatment of certain disease states refractory to treatment with calcineurin inhibitors. This alternative tcr activation pathway uniquely exists in a subset of cd8 t cells expanded in the setting of chronic rejection or rheumatoid arthritis.
Dna vaccines encoding heat shock proteins
A method of treating a t cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (hsp 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (iddm) or rheumatoid arthritis.
Alma Bio Therapeutics
Method for predicting therapeutic effect of biological preparation on rheumatoid arthritis
By using at least one serum concentration selected from the group consisting of sgp130, ip-10, stnfri, stnfrii, gm-csf, il-1β, il-2, il-5, il-6, il-7, il-8, il-9, il-12, il-13, il-15, eotaxin, vegf, mcp-1, tnf-α, ifn-γ, fgf basic, pdgf-bb sil-6r and mip-1α, the therapeutic effect (improvement of symptoms and possibility of response) of an inflammatory cytokine-targeting biological preparation on a patient having rheumatoid arthritis can be predicted in any type of facility in a simple, inexpensive, and highly accurate manner before administering the biological preparation.. .
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to c5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, goodpasture's syndrome, and chronic obstructive pulmonary disease.. .
Alexion Pharmaceuticals, Inc.
Uses of sesquiterpene lactone compounds and their derivatives in drugs preparation
The present invention relates to the uses of sesquiterpene lactone compounds and their derivatives in preparing drugs. It belongs to the field of drug technology, specifically relates to the uses of the compounds of formula (i) in preparing the drugs, especially the uses in preparing the drugs to treat rheumatoid arthritis and treat cancers through inhibiting cancer stem cells..
Promotion of lymphatic function
The present invention refers to lipophilic extracts of members of the iridaceae family, such as iris germanica and/or iris pallida, that have been found to promote lymphatic function. These extracts are suitable for the treatment of skin inflammation, rheumatoid arthritis, impaired wound healing, chronic inflammatory diseases, chronic airway inflammation, inflammatory bowel disease, rosacea, primary and/or secondary lymphedemas.
Compounds targeting proteins, compositions, methods, and uses thereof
The present invention provides modulators of protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses.
Therapeutic immune modulation by stem cell secreted exosomes
Disclosed are methods, compositions of matter, and protocols useful for the induction of a therapeutic immune modulatory response through administration of exosomes derived from a stem cell source. In one embodiment, said stem cell source is endometrial regenerative cells.
Xon Cells, Inc.
Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors
Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.. .
Potent lna oligonucleotides for the inhibition of hif-1a expression
The present disclosure relates to an lna oligonucleotide consisting of a sequence selected from the group consisting of 5′-(tx)gxgxcsasasgscsastscscstxgxt-3′ and 5′-(gx)txtxascstsgscscststscstxtxa-3′, wherein capital letters designate a beta-d-oxy-lna nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-d-oxy-lna nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link between neighbouring nucleotides/lna nucleotide analogues, and subscript “x” designates either a phosphorothioate link or a phosphorodiester link between neighbouring nucleotides/lna nucleotide analogues, and wherein the sequence is optionally extended by up to five 2-deoxynucleotide units. The lna oligonucleotides are useful for modulating the expression of hypoxia-inducible factor-1a (hif-1a), e.g.
Roche Innovation Center Copenhagen A/s
Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
The invention relates to neutralizing antibodies of gm-csf and compositions comprising the same for use in the treatment of inflammatory disorders such as rheumatoid arthritis according to specific dosing regimen. The invention relates also to neutralizing antibodies of gm-csf and compositions comprising the same for use in the treatment of pain, e.g.
Materials and methods for the development of an antigen-specific immune non-responsiveness state
The present invention provides materials and methods for making a subject non-responsive to an antigen. Methods of the invention may comprise contacting the subject with the antigen and a compound that induces anergy.
A&g Pharmaceutical, Inc
Compositions and methods of use for therapeutic antibodies
The present invention relates to antibodies that specifically bind to the baff receptor (baffr). The invention more specifically relates to specific antibodies that are baffr antagonists with in vivo b cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting b cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas..
Compositions and methods for immunomodulation in an organism
The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example il-15 (seq id no: 5, 6), il-2 (seq id no: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example il-15ra (seq id no: 7, 8), il-2ra (seq id no: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, scid, aids, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or lupus.
University Of Connecticut
Compositions and methods of treating lupus nephritis
The invention provides methods for treating or delaying progression of lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type ii anti-cd20 antibody.
Methods, agents and compositions for treatment of inflammatory conditions
The present invention relates to the screening, diagnosis, prognostic evaluation, and treatment or prevention of age associated inflammation, chronic inflammation, and inflammatory diseases. In particular, the present invention relates to treating or preventing inflammatory diseases (e.g.
Triazolone compounds as mpges-1 inhibitors
The present disclosure is directed to compounds of formula (i), and pharmaceutically acceptable salts thereof, as mpges-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin e synthase-1 (mpges-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases..
Glenmark Pharmaceuticals S.a.
Baff selective binding compounds and related methods
The present invention relates to peptide antagonists that bind with high specificity and affinity to b-lymphocyte stimulator (“baff”), thereby antagonizing baff receptor (“baff-r”) signaling. The invention more specifically relates to vnar single chain antibodies derived from nurse shark that bind to baff, baff antagonist compounds and compositions comprising a baff specific vnar binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo b cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete b cells, such as in autoimmune diseases including systemic lupus erythematosus (sle), rheumatoid arthritis (ra) or multiple sclerosis (ms), and in certain hematological cancers, including lymphomas, leukemias and myelomas..
Compositions and methods for immunomodulation in an organism
The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example il-15 (seq id no: 5, 6), il-2 (seq id no: 10, 12)or combinations of both, and an interleukin receptor polypeptide portion, for example il-15ra (seq id no: 7, 8), il-2ra (seq id no: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, scid, aids, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or lupus.
University Of Connecticut
Novel peptidomimetics with antiangiogenic activity
We disclose novel peptidomimetics with antiangiogenic activity and their uses, particularly in the treatment of neoplasms and chronic inflammation (in particular of: rheumatoid arthritis, colitis), in eczema, diabetes, age-related macular degeneration (armd), nephropathy and neuropathy, in particular for use in the form of intravenous infusions or injections, or implants releasing the active ingredient.. .
Uniwersytet Warszawski (heir Of The Deseased Inventor)
Heterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
4-substituted pyrrolo[2,3-d]pyrimidine compound and use thereof
The activity experimental results of the invention show that the new compound has obvious effect and activity in inhibition of janus kinases, jak-stat, cell proliferation of human lymphocytoma, and rheumatoid arthritis.. .
Rheumatoid Arthritis topics:
Follow us on Twitter
This listing is a sample listing of patent applications related to Rheumatoid Arthritis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Rheumatoid Arthritis with additional patents listed. Browse our RSS directory or Search for other possible listings.